News

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...
JPMorgan lowered the firm’s price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to ...
Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...
Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...
Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...